Document
IPR2023-00724, No. 2404 Exhibit - EX2404 US Food Drug Administration, DrugsFDA, Onglyza® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2404 Exhibit - EX2404 US Food Drug Administration, DrugsFDA, Onglyza® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2...
Cite Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes Po
+ More Snippets
Document
IPR2023-00724, No. 2525 Exhibit - EX2525 Eli Lilly Co, 2018 Financial Report (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2525 Exhibit - EX2525 Eli Lilly Co, 2018 Financial Report (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2379 Exhibit - EX2379 Novo Nordisk, “Managing your diabetes,” httpswwwmynovoinsulincomdiabetes educationmanaging diabeteshtml, last updated Dec 2022 (P.T.A.B. Ja...
Cite Document
IPR2023-00724, No. 2379 Exhibit - EX2379 Novo Nordisk, “Managing your diabetes,” httpswwwmynovoinsulincomdiabetes educationmanaging diabeteshtml, last updated Dec 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2103 Exhibit - EX2103 Marx, N, et al, GLP 1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes, Circulation, 14618...
Cite Document
IPR2023-00724, No. 2103 Exhibit - EX2103 Marx, N, et al, GLP 1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes, Circulation, 1461882 1894
+ More Snippets
Document
IPR2023-00724, No. 2437 Exhibit - EX2437 US Food Drug Administration, DrugsFDA, Tanzeum® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2437 Exhibit - EX2437 US Food Drug Administration, DrugsFDA, Tanzeum® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2521 Exhibit - EX2521 Bibeau, WS, et al, Impact of Out of Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes, J Manag Care ...
Cite Document
IPR2023-00724, No. 2521 Exhibit - EX2521 Bibeau, WS, et al, Impact of Out of Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes, J Manag Care Spec Pharm, 2016
+ More Snippets
Document
IPR2023-00724, No. 2503 Exhibit - EX2503 Novo Nordisk, Financial report for the period 1 January 2020 to 30 June 2020 Aug 6, 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2503 Exhibit - EX2503 Novo Nordisk, Financial report for the period 1 January 2020 to 30 June 2020 Aug 6, 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2094 Exhibit - EX2094 Eckel, RH and Blaha, MJ, Cardiometabolic Medicine A Call for a New Subspecialty Training Track in Internal Medicine, Am J Med, 1327788 790 2019...
Cite Document
IPR2023-00724, No. 2094 Exhibit - EX2094 Eckel, RH and Blaha, MJ, Cardiometabolic Medicine A Call for a New Subspecialty Training Track in Internal Medicine, Am J Med, 1327788 790 2019 (P.T.A.B. Jan
+ More Snippets
Document
IPR2023-00724, No. 2403 Exhibit - EX2403 Onglyza® Prescribing Information rev Feb 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2403 Exhibit - EX2403 Onglyza® Prescribing Information rev Feb 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2453 Exhibit - EX2453 US Food Drug Administration, DrugsFDA, Synjardy (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2453 Exhibit - EX2453 US Food Drug Administration, DrugsFDA, Synjardy (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2532 Exhibit - EX2532 Synjardy and Synjardy XR Prescribing Information rev Oct 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2532 Exhibit - EX2532 Synjardy and Synjardy XR Prescribing Information rev Oct 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2077 Exhibit - EX2077 Mueller, C, University of South Carolina Upstate, CHEM U109 Chemistry of Living Things, 91Solutions, available at httpschemlibretextsorgCoursesUn...
Cite Document
IPR2023-00724, No. 2077 Exhibit - EX2077 Mueller, C, University of South Carolina Upstate, CHEM U109 Chemistry of Living Things, 91Solutions, available at httpschemlibretextsorgCoursesUniversity of
+ More Snippets
Document
IPR2023-00724, No. 2407 Exhibit - EX2407 Victoza® Prescribing Information rev Nov 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2407 Exhibit - EX2407 Victoza® Prescribing Information rev Nov 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2354 Exhibit - EX2354 Centers for Disease Control and Prevention, “Gestational Diabetes,” httpswwwcdcgovdiabetesbasicsgestationalhtml, last reviewed Dec 30, 2022 (P....
Cite Document
IPR2023-00724, No. 2354 Exhibit - EX2354 Centers for Disease Control and Prevention, “Gestational Diabetes,” httpswwwcdcgovdiabetesbasicsgestationalhtml, last reviewed Dec 30, 2022 (P.T.A.B. Jan. 17
+ More Snippets